Q-omics provides the consensus-scored BCRP5 profile across patient tissues and cancer cell-line models. BCRP5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, BCRP5 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, BCRP5 RNA expression shows 6,026 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UCEC, and KIRC as cancer lineages where BCRP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCRP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCRP5 survival associations across molecular data types. BCRP5 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCRP5 RNA expression–survival associations across cancer types. High BCRP5 expression shows unfavorable associations in UCEC, COAD, TGCT, CHOL and READ, but favorable associations in UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify UCEC as the clearest survival context for BCRP5 RNA expression.
This table summarizes BCRP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BCRP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCRP5 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD and LIHC. The KIRC box plot shows higher BCRP5 RNA expression in tumor versus normal tissue (log2 FC = +0.165, t-test p = .011).
This table shows molecular features associated with BCRP5 in patient tissues and cancer cell lines. In patient samples, BCRP5 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
